Pulmonary hypertension as a risk assessment factor for unfavorable outcome in patients with COVID-19

Aim. To determine the predictive role of estimated pulmonary artery systolic pressure (ePASP) in COVID-19 patients.

Material and methods. A retrospective study of inpatients with documented COVID-19 infection was carried out. Maximal follow-up period was 63 days. The study included 108 patients (men, 62; women, 46; mean age, 62,9±15,5 years). At admission, mean NEWS score was 6,0, blood oxygen saturation — 92%. Echocardiography was performed according to standard protocol using Vivid E9 ultrasound system (GE Healthcare). Quantitative measurements were performed according to the current ASE and EACVI guidelines. Statistical analysis was performed using the IBM SPSS Statistics v.26 software (developed by IBM Corporation).

Results. Using the CHAID technique, a classification tree was developed and the strongest predictor of an unfavorable outcome was determined (ePASP). Threshold ePASP values, associated with an increased mortality risk were established (42 mm Hg and 50 mm Hg). Three groups of patients were selected based on the main predictor (<41,0 mm Hg, 42-49 mm Hg and >50 mm Hg). The increased mortality risk was noted in groups 2 and 3 compared to group 1 of patients and amounted to 31,8% and 70% versus 3,9%, respectively. There was also a correlation between the severity of CT lung parenchymal lesions according to computed tomography and the study groups of patients (36% [30-49%] — group 1, 50% [36-76%] — group 2, and 84% [56-92%] — group 3, p=0,001). In groups 2 and 3, the following complications were significantly more frequent: acute respiratory distress syndrome, acute heart failure, multiple organ system failure, venous thrombosis, disseminated intravascular coagulation. In group 3, acute renal failure and systemic inflammatory response syndrome developed significantly more often than in group 1.

Conclusion. A comprehensive echocardiography has proven its availability and safety in assessing the condition of COVID-19 patients, allowing to obtain relevant information on pulmonary hemodynamics. Transthoracic echocardiography reduced the risk of complications from invasive diagnostic methods and allowed to abandon the use of the Swan-Ganz pulmonary artery catheter in the studied group of patients. As a result, a relationship was noted between the increase of ePASP and the severity of clinical performance and lung tissue damage according to computed tomography, changes in laboratory blood tests, the severity of the comorbid profile, an increase in respiratory support need.

1. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-8. doi:10.1016/S0140-6736(20)30937-5.

2. Sylvester JT, Shimoda LA, Aaronson PI, et al. Hypoxic pulmonary vasoconstriction. Physiol Rev. 2012;92:367-520. doi:10.1152/physrev.00041.2010.

3. Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian clinical guidelines on diagnosis and treatment of pulmonary hypertention. Eurasian heart journal. 2020;(1):78-122. (In Russ.) doi:10.38109/2225-1685-2020-1-78-122.

4. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22(2):95-7.

5. Ribes A, Vardon-Bounes F, Memier V, et al. Thromboembolic events and Covid-19. Advances in Biological Regulation. 2020;77:100735. doi:10.1016/j.jbior.2020.100735.

6. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Translational Research. 2020;220:1-13. doi:10.1016/j.trsl.2020.04.007.

7. Fraga-Silva RA, Da Silva DG, Montecucco F, et al. The angiotensin-converting enzyme 2/ angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thrombosis and haemostasis. 2012;108(6):1089. doi:10.1160/TH12-06-0396.

8. Jardin F, Delorme G, Hardy A, et al. Reevaluation of hemodynamic consequences of positive pressure ventilation: emphasis on cyclic right ventricular afterloading by mechanical lung inflation. The Journal of the American Society of Anesthesiologists. 1990;72(6):966-70. doi:10.1097/00000542-199006000-00003.

9. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac camber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233-71. doi:10.1093/ehjci/jev014.

10. Voigt J-U, Pedrizzetti G, Lysyansky P, et al. Definition for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2015;16:1-11. doi:10.1093/ehjci/jeu184.

11. Zoghbi WA, Adams D, Bonow RO, et al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. Journal of the American Society of Echocardiography. 2017;30(4):303-71. doi:10.1016/j.echo.2017.01.007.

12. Previtero M, Guta AC, Ochoa-Jimenez RC, et al. 38 Prognostic validation of partition values obtained with conventional two-dimensional and doppler echocardiography to grade tricuspid regurgitation severity. European Heart Journal — Cardiovascular Imaging, 21, Issue Supplement_1. 2020. jez319. doi:10.1093/ehjci/jez319.

13. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713. doi:10.1016/j.echo.2010.05.010.

14. Hatle L, Angelsen BA, Tromsdal A. Non-invasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. Br Heart J. 1981;45:157-65. doi:10.1136/hrt.45.2.157.

15. Masuyama T, Kodama K, Kitakabe A, et al. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure. Circulation. 1986;74:484-92. doi:10.1161/01.CIR.74.3.484.

16. Alekhin MN, Zatejshhikova AA, Kiselev DG, et al. The value of echocardiographic assessment of the inferior vena cava for calculating the mean pressure in the pulmonary artery in patients with chronic obstructive pulmonary disease. Kremlin medicine. Clinical Bulletin. 2010;(2):64-7. (In Russ.)

17. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277-314. doi:10.1016/j.echo.2016.01.011.

18. World Health Organization. Rational use of personal protective equipment (PPE) for coronavirus disease (COVID-19): interim guidance, 19 March 2020 (WHO/2019-nCov/IPC PPE_use/2020.2). https://apps.who.int/iris/handle/10665/331498.

19. Kirkpatrick JN, Mitchell C, Taub C, et al. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak. Journal of the American College of Cardiology. 2020;33:648-53. doi:10.1016/j.jacc.2020.04.002.

20. Hung J, Abraham TP, Cohen MS, et al. ASE Statement on the Reintroduction of Echocardiographic Services during the COVID-19 Pandemic. J Am Soc Echocardiogr. 2020;33(8):1034-9. doi:10.1016/j.echo.2020.05.019.

21. Abramowicz JS, Basseal J. WFUMB Position Statement: How to perform a safe ultrasound examination and clean equipment in the context of COVID-19 On behalf of the WFUMB Safety Committee. https://wfumb.info/wp-content/uploads/2020/03/WFUMB-covid19-document_FINAL2.pdf.

22. Mitchell C, Collins K, Hua L, et al. Specific Considerations for Sonographers When Performing Echocardiography during the 2019 Novel Coronavirus Outbreak: Supplement to the American Society of Echocardiography Statement. J Am Soc Echocardiogr. 2020;33(6):654-7. doi:10.1016/j.echo.2020.04.014.

23. McQuillan BM, Picard MH, Leavitt M, et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation. 2001;104(23):2797-802. doi:10.1161/hc4801.100076.

24. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119(16):2250-94. doi:10.1016/j.jacc.2009.01.004.

25. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30(20):2493-537. doi:10.1093/eurheartj/ehp297.

26. Galie N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) [published correction appears in Eur Respir J. 2015;46(6):1855-6.] Eur Respir J. 2015;46(4):903-75. doi:10.1183/13993003.01032-2015.

27. Kanwar M, Raina A, Lohmueller L, et al. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension. Curr Hypertens Rep. 2019;21(6):45. doi:10.1007/s11906-019-0950-y.

28. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5.

29. Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clinical Research in Cardiology. 2020;109(5):531-8. doi:10.1007/s00392-020-01626-9.

30. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3.

31. Gusev DA, Vashukova MA, Fedunyak IP, et al. Experience with the use of a recombinant humanized monoclonal antibody to the human interleukin-6 receptor in patients with COVID-19. Journal of Infectology. 2020;12(3):28-33. (In Russ.) doi:10.22625/2072-6732-2020-12-3-28-33.

32. Li Y, Li H, Zhu S, et al. Prognostic Value of Right Ventricular Longitudinal Strain in Patients with COVID-19. JACC Cardiovasc Imaging. 2020:S1936-878X(20)30342-9. doi:10.1016/j.jcmg.2020.04.014.

33. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. Journal of the American College of Cardiology. 2013;62(25 Supplement):D42-D50. doi:10.1016/j.jacc.2013.10.032.

34. Greiner S, Jud A, Aurich M, et al. Reliability of noninvasive assessment of systolic pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: analysis in a large patient population. Journal of the American Heart Association. 2014;3(4):e001103. doi:10.1161/JAHA.114.001103.

35. Lanzarini L, Fontana A, Lucca E, et al. Noninvasive estimation of both systolic and diastolic pulmonary artery pressure from Doppler analysis of tricuspid regurgitant velocity spectrum in patients with chronic heart failure. Am Heart J. 2002;144(6):1087-94. doi:10.1067/mhj.2002.126350.

36. Lindqvist P, Soderberg S, Gonzalez MC, et al. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. Eur J Echocardiogr. 2011;12(12):961-6. doi:10.1093/ejechocard/jer222.

37. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. European Respiratory Journal. 2009;34:888-94. doi:10.1183/09031936.00145608.

38. Nagueh SF, Middleton KJ, Kopelen HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol. 1997;30(6):1527-33. doi:10.1016/s0735-1097(97)00344-6.

39. Bossone E, D’Andrea A, D’Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. Journal of the American Society of Echocardiography. 2013;26:1-14. doi:10.1016/j.echo.2012.10.009.

40. Ryan JJ, Rich JD, Thiruvoipati T, et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J. 2012;163(4):589-94. doi:10.1016/j.ahj.2012.01.024.

41. Which increases the risk of an adverse outcome in the case of COVID-19? 2020. (In Russ.) https://bakulev.ru/news/glavnoe/chto-povyshaet-risk-neblagopriyatnogo-iskhoda-pri-zabolevanii-covid-19/.